Coya Therapeutics reports Q2 2026 results, updates ALSTARS trial and FTD plans
Coya said its first ALSTARS cohort has moved into a blinded extension phase and it still expects topline ALS data in early 2027, with cash reaching $43.2 million.
SEC filing